Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis	Neoplasms by Site, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges	Active, not recruiting	Phase 1 / Phase 2	2026-09-02		NCT06809530

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Guangzhou Medical University	33

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine	Beijing	China	1
Beijing Chest Hospital, Capital Medical University	Beijing	China	3
Huizhou First Hospital Affiliated to Guangdong Medical University	Huizhou	China	2
Jinshan Hospital, Fudan University	Shanghai	China	3
The Affiliated Huizhou Hospital, Guangzhou Medical University	Huizhou	China	6